Physician profile
Rachel Marie Duke
NPI 1063716033
$750,605.69
in general payments reported to CMS, 2019-2025
6 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125K · 2022: $220K · 2023: $144K · 2024: $148K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $345K · Travel and Lodging: $51K · Food and Beverage: $9,103 · Consulting Fee: $748 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $345,446.25 |
| Travel and Lodging | $50,719.04 |
| Food and Beverage | $9,102.80 |
| Consulting Fee | $748.17 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403,127.71 | 2022-2025 | |
| Allergan, INC. | $344,148.68 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $2,597.85 | 2021-2025 | |
| Galderma Laboratories, L.P. | $602.37 | 2021-2025 | |
| Revance Therapeutics, INC. | $86.77 | 2024-2025 | Daxxify |
| Biogen, INC. | $42.31 | 2023 | Tysabri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.